MGX — Metagenomi Therapeutics, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1785279 ·
Last close
$0.63
Market Cap
$23.86M
52W High
$1.87
52W Low
$0.60
ADV30
183,198
Next earnings
—
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 2,184,000 — -22,226,000 -21,126,000 157,388,000 36,107,000 64,200,000
Jun 2026 -257,000 — -28,773,000 -27,482,000 173,701,000 39,028,000 61,134,000
Mar 2026 1,248,000 — -24,587,000 -23,059,000 196,953,000 25,306,000 59,168,000
Dec 2025 3,911,000 — -24,367,000 -22,528,000 221,103,000 41,722,000 62,507,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-83,317,000
Investing CF
$85,682,000
Financing CF
$114,000
CapEx
$-309,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.45
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-382,537,000
Inventory
—
Receivables
$0
ST Investments
$65,567,000
EBIT TTM
$-99,953,000
Pretax Income TTM
$-94,151,000
Interest Exp TTM
—
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$7,086,000
EBITDA
$-94,859,000
Free Cash Flow
$-47,260,624
Enterprise Value
$-39,311,820
Total Cash
$101,674,000
Total Debt
$36,212,000
Shares Out
37,805,669
Trailing EPS
$-2.50
Book Value
$2.46
ROE
-69.4%
ROA
-30.8%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 25,210,000 -96,013,000 -87,868,000 221,103,000 62,507,000 158,596,000 -88,892,000
Dec 2024 52,295,000 -88,901,000 -78,058,000 324,599,000 89,742,000 234,857,000 -109,073,000
Dec 2023 44,756,000 -78,492,000 -68,255,000 364,842,000 500,426,000 -135,584,000 -91,409,000
Dec 2022 17,200,000 -44,640,000 -43,593,000 414,486,000 488,914,000 -74,428,000 29,724,000

TTM Snapshot

Revenues TTM
$15,074,000
NetIncome TTM
$-93,462,000
OpCashFlow TTM
—
Assets (Latest)
$173,701,000
Forward EPS
$-1.83

Peers — same industry

TickerNameMarket CapLastDaily %
ZIVO Zivo Bioscience, Inc. $23.18M $5.50 —
EVAX Evaxion A/S $25.08M $2.78 —
LONA LeonaBio, Inc. $26.00M $2.76 —
PTHS Pelthos Therapeutics Inc. $26.89M $6.84 —
SAEN Genenta Science S.p.A. $27.82M $0.58 —

News headlines (Yahoo Finance, 1h cache)

Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference in London
2026-11-11 13:00 · Yahoo
Metagenomi Therapeutics: Q3 Earnings Snapshot
2026-11-10 22:14 · Yahoo
Metagenomi Therapeutics Announces FDA Clearance of Investigational New Drug Application for MGX-001 and Reports Third Quarter 2026 Financial Results
2026-11-10 21:05 · Yahoo
Metagenomi Therapeutics to Present Preclinical Data Supporting MGX-001, a Potential One-Time Therapy for Hemophilia A, in Oral Presentation at 68th American Society of Hematology Annual Meeting
2026-11-04 14:25 · Yahoo
Metagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare Conference
2026-10-13 12:00 · Yahoo
Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
2026-09-01 12:00 · Yahoo
Metagenomi Therapeutics (MGX) Reports Q2 Loss, Lags Revenue Estimates
2026-08-10 21:55 · Yahoo
Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
2026-08-10 20:05 · Yahoo
Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
2026-05-11 20:05 · Yahoo
Metagenomi Therapeutics (MGX) Reports Q1 Loss, Misses Revenue Estimates
2026-05-12 00:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.